Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Top Cited Papers
- 22 February 2020
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 209, 107512
- https://doi.org/10.1016/j.pharmthera.2020.107512
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 125 references indexed in Scilit:
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In VitroJournal of Virology, 2013
- Negative Regulation of Lung Inflammation and Immunopathology by TNF-α during Acute Influenza InfectionThe American Journal of Pathology, 2011
- Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease modelsAntiviral Research, 2010
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2009
- Effect of T-705 treatment on western equine encephalitis in a mouse modelAntiviral Research, 2009
- Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106Antimicrobial Agents and Chemotherapy, 2009
- Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsAntiviral Research, 2008
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008
- In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in MiceAntimicrobial Agents and Chemotherapy, 2007